



Developing a referral pathway for patients with Breast Liver Metastases

Authors: Mr Thomas Satyadas, Ms Clare Garnsey, Claire Goldrick


Affiliations: Greater Manchester Cancer, Manchester University Foundation Trust, Bolton NHS Foundation Trust

Treatment for patients with Breast Liver Metastases

There is currently no dedicated treatment pathway available for patients with Breast Liver Metastases. Although there is no robust evidence for Liver targeted treatment by surgery, ablation, or Stereotactic Ablative Radiotherapy (SABR), there is increasing evidence that Liver targeted therapy provides reasonable overall and disease-free survival for selected Breast Cancer patients with Liver Metastases.

Historically, there have been sporadic referrals to the Hepato-Pancreato-Biliary (HPB) Specialist Multidisciplinary Team (sMDT) to review and discuss potential treatment options causing inequity of access to treatment for patients across Greater Manchester.

With appropriate patient selection and direct involvement of Breast Oncologists, Liver targeted therapy using surgery, ablation or SABR could potentially provide better outcomes for a select proportion of Breast Cancer patients with Liver Metastases.



Over the next twelve months, an audit of referrals will be conducted to assess quality and equity of access to treatment as well as the creation of a support group for patients treated for Breast Liver Metastases in Greater Manchester.